Does the media favor ZVRA or WHWK?

In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 1 articles in the media. Zevra Therapeutics' average media sentiment score of 0.00 equaled Whitehawk Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer WHWK or CYRX?

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 1 articles in the media. Whitehawk Therapeutics' average media sentiment score of 0.00 equaled CryoPort'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor WHWK or SPRY?

In the previous week, ARS Pharmaceuticals had 5 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 1 mentions for Whitehawk Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.31 beat Whitehawk Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Whitehawk Therapeutics (WHWK) Competitors

$4.19 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.36 +0.18 (+4.18%)

As of 07/2/2026 05:27 PM Eastern

Compare

WHWK vs. PHAT, ZVRA, ESPR, CYRX, and SPRY

Should you buy Whitehawk Therapeutics stock or one of its competitors? MarketBeat compares Whitehawk Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Whitehawk Therapeutics include Phathom Pharmaceuticals (PHAT), Zevra Therapeutics (ZVRA), Esperion Therapeutics (ESPR), CryoPort (CYRX), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry.

How does Whitehawk Therapeutics compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Phathom Pharmaceuticals currently has a consensus target price of $24.50, suggesting a potential upside of 118.75%. Whitehawk Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 90.93%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Whitehawk Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	5.10	-$221.25M	-$2.12	N/A
Whitehawk Therapeutics	$7.14M	29.02	-$20.60M	-$1.68	N/A

Phathom Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 1 mentions for Whitehawk Therapeutics and 0 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 0.00 equaled Whitehawk Therapeutics'average media sentiment score.

Company	Overall Sentiment
Phathom Pharmaceuticals	Neutral
Whitehawk Therapeutics	Neutral

Whitehawk Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Whitehawk Therapeutics beats Phathom Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 1 articles in the media. Zevra Therapeutics' average media sentiment score of 0.00 equaled Whitehawk Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics has a net margin of 101.58% compared to Whitehawk Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

Zevra Therapeutics currently has a consensus target price of $29.29, indicating a potential upside of 109.48%. Whitehawk Therapeutics has a consensus target price of $8.00, indicating a potential upside of 90.93%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Zevra Therapeutics is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Zevra Therapeutics has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.76	$83.23M	$1.99	7.03
Whitehawk Therapeutics	$7.14M	29.02	-$20.60M	-$1.68	N/A

Zevra Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Zevra Therapeutics beats Whitehawk Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Esperion Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

In the previous week, Whitehawk Therapeutics had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 1 mentions for Whitehawk Therapeutics and 0 mentions for Esperion Therapeutics. Esperion Therapeutics' average media sentiment score of 0.00 equaled Whitehawk Therapeutics'average media sentiment score.

Company	Overall Sentiment
Esperion Therapeutics	Neutral
Whitehawk Therapeutics	Neutral

Esperion Therapeutics currently has a consensus price target of $5.54, suggesting a potential upside of 75.32%. Whitehawk Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 90.93%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Whitehawk Therapeutics has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.02	-$22.68M	-$0.06	N/A
Whitehawk Therapeutics	$7.14M	29.02	-$20.60M	-$1.68	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Whitehawk Therapeutics' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Whitehawk Therapeutics	N/A	-79.63%	-74.01%

Summary

Whitehawk Therapeutics beats Esperion Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to CryoPort?

Whitehawk Therapeutics (NASDAQ:WHWK) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Whitehawk Therapeutics and Whitehawk Therapeutics both had 1 articles in the media. Whitehawk Therapeutics' average media sentiment score of 0.00 equaled CryoPort'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CryoPort has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	29.02	-$20.60M	-$1.68	N/A
CryoPort	$182.94M	4.27	$78.30M	$1.35	11.47

CryoPort has a net margin of 41.57% compared to Whitehawk Therapeutics' net margin of 0.00%. CryoPort's return on equity of -7.92% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
CryoPort	41.57%	-7.92%	-4.79%

Whitehawk Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by company insiders. Comparatively, 10.0% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Whitehawk Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 90.93%. CryoPort has a consensus price target of $15.11, indicating a potential downside of 2.45%. Given Whitehawk Therapeutics' higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

CryoPort beats Whitehawk Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to ARS Pharmaceuticals?

Whitehawk Therapeutics (NASDAQ:WHWK) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Whitehawk Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 90.93%. ARS Pharmaceuticals has a consensus target price of $28.20, suggesting a potential upside of 229.44%. Given ARS Pharmaceuticals' higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Whitehawk Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	29.02	-$20.60M	-$1.68	N/A
ARS Pharmaceuticals	$84.28M	10.09	-$171.30M	-$2.01	N/A

Whitehawk Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 5 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 1 mentions for Whitehawk Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.31 beat Whitehawk Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Whitehawk Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Whitehawk Therapeutics' return on equity of -79.63% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Summary

Whitehawk Therapeutics beats ARS Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WHWK vs. The Competition

Export

Metric	Whitehawk Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$207.20M	$791.44M	$5.21B	$12.47B
Dividend Yield	N/A	4.84%	16.10%	6.50%
P/E Ratio	-2.49	1.66	23.91	24.70
Price / Sales	29.02	116.91	168.34	97.92
Price / Cash	N/A	20.06	35.06	57.09
Price / Book	1.45	8.17	13.25	6.46
Net Income	-$20.60M	-$3.71M	$113.80M	$337.01M
7 Day Performance	0.72%	2.59%	0.93%	1.69%
1 Month Performance	0.96%	4.41%	1.08%	3.81%
1 Year Performance	110.55%	49.43%	10.03%	23.90%

Whitehawk Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WHWK Whitehawk Therapeutics	2.4391 of 5 stars	$4.19 flat	$8.00 +90.9%	+110.6%	$207.20M	$7.14M	N/A	21	Gap Up
PHAT Phathom Pharmaceuticals	1.5953 of 5 stars	$11.20 +6.4%	$24.50 +118.8%	+27.8%	$840.23M	$175.11M	N/A	110
ZVRA Zevra Therapeutics	4.1305 of 5 stars	$13.98 +1.2%	$29.29 +109.5%	+42.9%	$816.38M	$122.29M	7.03	20
ESPR Esperion Therapeutics	3.101 of 5 stars	$3.16 flat	$5.54 +75.3%	+169.9%	$814.31M	$403.14M	N/A	200	Positive News
CYRX CryoPort	3.4036 of 5 stars	$15.49 -2.3%	$15.11 -2.4%	+102.7%	$799.38M	$176.18M	11.47	1,186	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WHWK) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. PHAT, ZVRA, ESPR, CYRX, and SPRY

How does Whitehawk Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Whitehawk Therapeutics compare to Zevra Therapeutics?

Summary

How does Whitehawk Therapeutics compare to Esperion Therapeutics?

Summary

How does Whitehawk Therapeutics compare to CryoPort?

Summary

How does Whitehawk Therapeutics compare to ARS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. PHAT, ZVRA, ESPR, CYRX, and SPRY

How does Whitehawk Therapeutics compare to Phathom Pharmaceuticals?

Do analysts recommend PHAT or WHWK?

Which has better earnings and valuation, PHAT or WHWK?

Which has more volatility and risk, PHAT or WHWK?

Does the media prefer PHAT or WHWK?

Is PHAT or WHWK more profitable?

Do insiders & institutionals hold more shares of PHAT or WHWK?

Summary

How does Whitehawk Therapeutics compare to Zevra Therapeutics?

Does the media favor ZVRA or WHWK?

Is ZVRA or WHWK more profitable?

Do analysts rate ZVRA or WHWK?

Which has stronger earnings and valuation, ZVRA or WHWK?

Which has more risk & volatility, ZVRA or WHWK?

Do insiders & institutionals believe in ZVRA or WHWK?

Summary

How does Whitehawk Therapeutics compare to Esperion Therapeutics?

Do insiders and institutionals have more ownership in ESPR or WHWK?

Which has more risk & volatility, ESPR or WHWK?

Does the media favor ESPR or WHWK?

Do analysts prefer ESPR or WHWK?

Which has better earnings & valuation, ESPR or WHWK?

Is ESPR or WHWK more profitable?

Summary

How does Whitehawk Therapeutics compare to CryoPort?

Does the media prefer WHWK or CYRX?

Which has stronger earnings & valuation, WHWK or CYRX?

Is WHWK or CYRX more profitable?

Which has more risk and volatility, WHWK or CYRX?

Do insiders & institutionals have more ownership in WHWK or CYRX?

Do analysts prefer WHWK or CYRX?

Summary

How does Whitehawk Therapeutics compare to ARS Pharmaceuticals?

Do analysts recommend WHWK or SPRY?

Which has higher earnings & valuation, WHWK or SPRY?

Which has more volatility & risk, WHWK or SPRY?

Does the media favor WHWK or SPRY?

Do insiders and institutionals have more ownership in WHWK or SPRY?

Is WHWK or SPRY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools